DrugAgent: Explainable Drug Repurposing Agent with Large Language Model-based Reasoning

• URL: http://arxiv.org/abs/2408.13378v3
• Date: Mon, 16 Sep 2024 22:13:30 GMT
• Title: DrugAgent: Explainable Drug Repurposing Agent with Large Language Model-based Reasoning
• Authors: Yoshitaka Inoue, Tianci Song, Tianfan Fu,
• Abstract summary: We propose a multi-agent framework to enhance the drug repurposing process using state-of-the-art machine learning techniques and knowledge integration. Our framework comprises several specialized agents: an AI Agent trains robust drug-target interaction (DTI) models; a Knowledge Graph Agent utilizes the drug-gene interaction database (DGIdb) to systematically extract DTIs. By integrating outputs from these agents, our system effectively harnesses diverse data sources, including external databases, to propose viable repurposing candidates.
• Score: 10.528489471229946
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: Drug repurposing offers a promising avenue for accelerating drug development by identifying new therapeutic potentials of existing drugs. In this paper, we propose a multi-agent framework to enhance the drug repurposing process using state-of-the-art machine learning techniques and knowledge integration. Our framework comprises several specialized agents: an AI Agent trains robust drug-target interaction (DTI) models; a Knowledge Graph Agent utilizes the drug-gene interaction database (DGIdb), DrugBank, Comparative Toxicogenomics Database (CTD), and Search Tool for Interactions of Chemicals (STITCH) to systematically extract DTIs; and a Search Agent interacts with biomedical literature to annotate and verify computational predictions. By integrating outputs from these agents, our system effectively harnesses diverse data sources, including external databases, to propose viable repurposing candidates. Preliminary results demonstrate the potential of our approach in not only predicting drug-disease interactions but also in reducing the time and cost associated with traditional drug discovery methods. This paper highlights the scalability of multi-agent systems in biomedical research and their role in driving innovation in drug repurposing. Our approach not only outperforms existing methods in predicting drug repurposing potential but also provides interpretable results, paving the way for more efficient and cost-effective drug discovery processes.

Related papers

• LLM Agent Swarm for Hypothesis-Driven Drug Discovery [2.7036595757881323]
  PharmaSwarm is a unified multi-agent framework that orchestrates specialized "agents" to propose, validate, and refine hypotheses for novel drug targets and lead compounds. By acting as an AI copilot, PharmaSwarm can accelerate translational research and deliver high-confidence hypotheses more efficiently than traditional pipelines.
  arXiv  Detail & Related papers  (2025-04-24T22:27:50Z)
• TAMA: A Human-AI Collaborative Thematic Analysis Framework Using Multi-Agent LLMs for Clinical Interviews [54.35097932763878]
  Thematic analysis (TA) is a widely used qualitative approach for uncovering latent meanings in unstructured text data. Here, we propose TAMA: A Human-AI Collaborative Thematic Analysis framework using Multi-Agent LLMs for clinical interviews. We demonstrate that TAMA outperforms existing LLM-assisted TA approaches, achieving higher thematic hit rate, coverage, and distinctiveness.
  arXiv  Detail & Related papers  (2025-03-26T15:58:16Z)
• Collaborative Expert LLMs Guided Multi-Objective Molecular Optimization [51.104444856052204]
  We present MultiMol, a collaborative large language model (LLM) system designed to guide multi-objective molecular optimization. In evaluations across six multi-objective optimization tasks, MultiMol significantly outperforms existing methods, achieving a 82.30% success rate.
  arXiv  Detail & Related papers  (2025-03-05T13:47:55Z)
• RAG-Enhanced Collaborative LLM Agents for Drug Discovery [28.025359322895905]
  CLADD is a retrieval-augmented generation (RAG)-empowered agentic system tailored to drug discovery tasks. We show that it outperforms general-purpose and domain-specific LLMs as well as traditional deep learning approaches.
  arXiv  Detail & Related papers  (2025-02-22T00:12:52Z)
• Exploring Multi-Modal Integration with Tool-Augmented LLM Agents for Precise Causal Discovery [45.777770849667775]
  Causal inference is an imperative foundation for decision-making across domains, such as smart health, AI for drug discovery and AIOps. We introduce MATMCD, a multi-agent system powered by tool-augmented LLMs. Our empirical study suggests the significant potential of multi-modality enhanced causal discovery.
  arXiv  Detail & Related papers  (2024-12-18T09:50:00Z)
• DrugAgent: Automating AI-aided Drug Discovery Programming through LLM Multi-Agent Collaboration [31.892593155710625]
  We introduce DrugAgent, a multi-agent framework aimed at automating machine learning (ML) programming in drug discovery. DrugAgent incorporates domain expertise by identifying specific requirements and building domain-specific tools, while systematically exploring different ideas to find effective solutions. For example, DrugAgent is able to complete the ML programming pipeline end-to-end, from data acquisition to performance evaluation for the ADMET prediction task, and finally select the best model.
  arXiv  Detail & Related papers  (2024-11-24T03:06:59Z)
• MIN: Multi-channel Interaction Network for Drug-Target Interaction with Protein Distillation [64.4838301776267]
  Multi-channel Interaction Network (MIN) is a novel framework designed to predict drug-target interaction (DTI) MIN incorporates a representation learning module and a multi-channel interaction module. MIN is not only a potent tool for DTI prediction but also offers fresh insights into the prediction of protein binding sites.
  arXiv  Detail & Related papers  (2024-11-23T05:38:36Z)
• Large Language Models in Drug Discovery and Development: From Disease Mechanisms to Clinical Trials [49.19897427783105]
  The integration of Large Language Models (LLMs) into the drug discovery and development field marks a significant paradigm shift. We investigate how these advanced computational models can uncover target-disease linkage, interpret complex biomedical data, enhance drug molecule design, predict drug efficacy and safety profiles, and facilitate clinical trial processes.
  arXiv  Detail & Related papers  (2024-09-06T02:03:38Z)
• Inquire, Interact, and Integrate: A Proactive Agent Collaborative Framework for Zero-Shot Multimodal Medical Reasoning [21.562034852024272]
  The adoption of large language models (LLMs) in healthcare has attracted significant research interest. Most state-of-the-art LLMs are unimodal, text-only models that cannot directly process multimodal inputs. We propose a multimodal medical collaborative reasoning framework textbfMultiMedRes to solve medical multimodal reasoning problems.
  arXiv  Detail & Related papers  (2024-05-19T18:26:11Z)
• Learning to Describe for Predicting Zero-shot Drug-Drug Interactions [54.172575323610175]
  Adverse drug-drug interactions can compromise the effectiveness of concurrent drug administration. Traditional computational methods for DDI prediction may fail to capture interactions for new drugs due to the lack of knowledge. We propose TextDDI with a language model-based DDI predictor and a reinforcement learning(RL)-based information selector.
  arXiv  Detail & Related papers  (2024-03-13T09:42:46Z)
• Multiscale Topology in Interactomic Network: From Transcriptome to Antiaddiction Drug Repurposing [0.3683202928838613]
  The escalating drug addiction crisis in the United States underscores the urgent need for innovative therapeutic strategies. This study embarked on an innovative and rigorous strategy to unearth potential drug repurposing candidates for opioid and cocaine addiction treatment.
  arXiv  Detail & Related papers  (2023-12-03T04:01:38Z)
• Emerging Drug Interaction Prediction Enabled by Flow-based Graph Neural Network with Biomedical Network [69.16939798838159]
  We propose EmerGNN, a graph neural network (GNN) that can effectively predict interactions for emerging drugs. EmerGNN learns pairwise representations of drugs by extracting the paths between drug pairs, propagating information from one drug to the other, and incorporating the relevant biomedical concepts on the paths. Overall, EmerGNN has higher accuracy than existing approaches in predicting interactions for emerging drugs and can identify the most relevant information on the biomedical network.
  arXiv  Detail & Related papers  (2023-11-15T06:34:00Z)
• PGraphDTA: Improving Drug Target Interaction Prediction using Protein Language Models and Contact Maps [4.590060921188914]
  Key aspect of drug discovery involves identifying novel drug-target (DT) interactions. Protein-ligand interactions exhibit a continuum of binding strengths, known as binding affinity. We propose novel enhancements to enhance their performance.
  arXiv  Detail & Related papers  (2023-10-06T05:00:25Z)
• Quantifying & Modeling Multimodal Interactions: An Information Decomposition Framework [89.8609061423685]
  We propose an information-theoretic approach to quantify the degree of redundancy, uniqueness, and synergy relating input modalities with an output task. To validate PID estimation, we conduct extensive experiments on both synthetic datasets where the PID is known and on large-scale multimodal benchmarks. We demonstrate their usefulness in (1) quantifying interactions within multimodal datasets, (2) quantifying interactions captured by multimodal models, (3) principled approaches for model selection, and (4) three real-world case studies.
  arXiv  Detail & Related papers  (2023-02-23T18:59:05Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• KGML-xDTD: A Knowledge Graph-based Machine Learning Framework for Drug Treatment Prediction and Mechanism Description [11.64859287146094]
  We propose KGML-xDTD: a Knowledge Graph-based Machine Learning framework for explainably predicting Drugs Treating Diseases. We leverage knowledge-and-publication based information to extract biologically meaningful "demonstration paths" as the intermediate guidance in the Graph-based Reinforcement Learning process.
  arXiv  Detail & Related papers  (2022-11-30T17:05:22Z)
• SSM-DTA: Breaking the Barriers of Data Scarcity in Drug-Target Affinity Prediction [127.43571146741984]
  Drug-Target Affinity (DTA) is of vital importance in early-stage drug discovery. wet experiments remain the most reliable method, but they are time-consuming and resource-intensive. Existing methods have primarily focused on developing techniques based on the available DTA data, without adequately addressing the data scarcity issue. We present the SSM-DTA framework, which incorporates three simple yet highly effective strategies.
  arXiv  Detail & Related papers  (2022-06-20T14:53:25Z)
• Multi-View Substructure Learning for Drug-Drug Interaction Prediction [69.34322811160912]
  We propose a novel multi- view drug substructure network for DDI prediction (MSN-DDI) MSN-DDI learns chemical substructures from both the representations of the single drug (intra-view) and the drug pair (inter-view) simultaneously and utilizes the substructures to update the drug representation iteratively. Comprehensive evaluations demonstrate that MSN-DDI has almost solved DDI prediction for existing drugs by achieving a relatively improved accuracy of 19.32% and an over 99% accuracy under the transductive setting.
  arXiv  Detail & Related papers  (2022-03-28T05:44:29Z)
• Multiple Similarity Drug-Target Interaction Prediction with Random Walks and Matrix Factorization [16.41618129467975]
  We take a multi-layered network perspective, where different layers correspond to different similarity metrics between drugs and targets. To fully take advantage of topology information captured in multiple views, we develop an optimization framework, called MDMF, for DTI prediction. The framework learns vector representations of drugs and targets that not only retain higher-order proximity across all hyper-layers, but also approximates the interactions with their inner product.
  arXiv  Detail & Related papers  (2022-01-24T08:02:05Z)
• Ensemble Transfer Learning for the Prediction of Anti-Cancer Drug Response [49.86828302591469]
  In this paper, we apply transfer learning to the prediction of anti-cancer drug response. We apply the classic transfer learning framework that trains a prediction model on the source dataset and refines it on the target dataset. The ensemble transfer learning pipeline is implemented using LightGBM and two deep neural network (DNN) models with different architectures.
  arXiv  Detail & Related papers  (2020-05-13T20:29:48Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.